Biotechnology

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

A massive $125M investment empowers five international teams to pursue radical ideas, from cancer-proof people to self-destructing tumors.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

A new patented drug, budiodarone, aims to treat atrial fibrillation in heart failure patients, a group with few safe options. Is this the future of care?

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

Finance and governance powerhouse Suzanne Nora Johnson joins Wellcome Leap's board, a strategic move to supercharge its mission to solve health crises.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

Biopharma toolmaker Ensorcell appoints Geoff Hodge and Amy Teachout, signaling a strategic move to disrupt the market with affordable, US-made innovation.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

A new 'scar-less' protein purification technology promises to slash development timelines for complex biologics, accelerating the path to new medicines.

A novel sputum test could end the trial-and-error approach for millions with chronic respiratory disease, promising a new era of personalized medicine.

With a soaring stock and a breakthrough CAR-T therapy, Immix Biopharma is set to capture investor attention. What's behind the hype for its lead drug, NXC-201?

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.